What this is
- How it works
- How it works isn't classified yet
- Tested for
- Herpes Zoster
- Main trialPhase 2
- “To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.”In the company’s words, NCT07481604 on ClinicalTrials.gov
Other drugs for Herpes Zoster
- HZ/su vaccineGSK · Phase 3
- Recombinant Zoster VaccineMAXVAX Biotechnology Limited Liability Company · Phase 3
- SYS6017CSPC · Phase 2
- Z-1018Dynavax Technologies Corporation · Phase 1/2
- SYS6052CSPC · Phase 1/2
- HZ VaccineShenzhen Shenxin Biotechnology Co., Ltd · Phase 2
Coming up1
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jan 2027 | Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above | |
| Phase 1Completed | 21 Jan 2025 | Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026